Meadow Creek Investment Management’s Ligand Pharmaceuticals LGND Stock Holding History

Meadow Creek Investment Management’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$199K	Hold	3,206	–	–	﹤0.01%	1032
2019 Q2	$228K	Buy	3,206 +308	+11%	+$22.7K	﹤0.01%	999
2019 Q1	$227K	Hold	2,898	–	–	﹤0.01%	969
2018 Q4	$245K	Hold	2,898	–	–	0.01%	892
2018 Q3	$496K	Buy	2,898 +77	+3%	+$11.6K	0.01%	727
2018 Q2	$365K	Hold	2,821	–	–	0.01%	787
2018 Q1	$291K	Hold	2,821	–	–	0.01%	862
2017 Q4	$241K	Buy	2,821 +615	+28%	+$53.3K	0.01%	929
2017 Q3	$187K	Buy	2,206 +436	+25%	+$34.5K	﹤0.01%	938
2017 Q2	$134K	Buy	1,770 +821	+87%	+$57.4K	﹤0.01%	994
2017 Q1	$63K	Buy	949 +180	+23%	+$11.8K	﹤0.01%	1087
2016 Q4	$49K	Buy	+769	New	+$48.5K	﹤0.01%	1125

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CCMLC

Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return

CCA

Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Meadow Creek Investment Management's LGND Position: Q3 2019 in Review

Meadow Creek Investment Management held its Ligand Pharmaceuticals (LGND) position steady in Q3 2019 at 3,206 shares worth $199K. The position accounts for ﹤0.01% of the portfolio, ranked #1032.

Meadow Creek Investment Management first reported a position in LGND in Q4 2016 and has held it in 12 quarters since. The position peaked at $496K in Q3 2018. 275 funds tracked by Wall St. Rank hold LGND as of Q3 2019.

Meadow Creek Investment Management held 3,206 shares of Ligand Pharmaceuticals worth $199K as of Q3 2019.
Meadow Creek Investment Management left its Ligand Pharmaceuticals share count unchanged in Q3 2019.
Ligand Pharmaceuticals made up ﹤0.01% of Meadow Creek Investment Management's portfolio in Q3 2019, its #1032 holding.
Meadow Creek Investment Management first reported a position in Ligand Pharmaceuticals in Q4 2016 and has held it in 12 quarters since.
Meadow Creek Investment Management's Ligand Pharmaceuticals position peaked at $496K in Q3 2018.
275 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2019.

Based on Meadow Creek Investment Management's 13F filing for Q3 2019, filed 14 Nov 2019.